Clarissa E. Vergunst

Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial

Clarissa E. Vergunst, Daniëlle M. Gerlag, Luba Lopatinskaya et al. · Arthritis & Rheumatism · 2008 · 236 citations

Life Sciences, Immunology, Pharmacology +17

Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation

Clarissa E. Vergunst, Daniëlle M. Gerlag, Huibert J. Dinant et al. · Lara D. Veeken · 2007 · 162 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker

Carla A. Wijbrandts, Clarissa E. Vergunst, Jasper J. Haringman et al. · Arthritis & Rheumatism · 2007 · 114 citations

Medicine, Immunology, Pathology +13

Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis

Maria C. Lebre, Clarissa E. Vergunst, Ivy Y. Choi et al. · PLoS ONE · 2011 · 83 citations · Full text

Medicine, Immunology, Internal Medicine +17

MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double‐blind, placebo‐controlled, randomized, proof‐of‐concept study

Clarissa E. Vergunst, Daniëlle M. Gerlag, Lisa Von Moltke et al. · Arthritis & Rheumatism · 2009 · 81 citations

Medicine, Pharmacology, Pharmacotherapy +13